Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
Pyxis Oncology (Nasdaq: PYXS) is set to host investor meetings on February 15, 2023, during the SVB Securities Global Biopharma Conference, which will occur virtually. Key executives attending include Lara Sullivan, M.D. (President & CEO), Pamela Connealy (CFO), Jay Feingold, M.D., Ph.D. (CMO), and Jan Pinkas, Ph.D. (CSO). Institutional investors interested in participating can contact their SVB Securities representative or Jennifer Davis Ruff, VP of Investor Relations.
Pyxis Oncology focuses on developing next-generation therapeutics aimed at difficult-to-treat cancers, utilizing strategies such as antibody-drug conjugates and immuno-oncology programs.
- None.
- None.
CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, Pamela Connealy, Chief Financial Officer, Jay Feingold, M.D., Ph.D., Chief Medical Officer, and Jan Pinkas, Ph.D., Chief Scientific Officer, will host investor meetings on February 15, 2023 as part of the SVB Securities Global Biopharma Conference, taking place virtually.
Institutional investors interested in meeting with management during the conference may reach out to their SVB Securities representative or Jennifer Davis Ruff, Investor Relations for Pyxis Oncology, at jdavisruff@pyxisoncology.com.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination therapies. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Pyxis Oncology’s antibody-drug conjugates (ADCs) and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care. To learn more, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would,” or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors” set forth in Part II, Item 1A. of the Company’s Quarterly Report on Form 10-Q filed with SEC on November 1, 2022 and in our other filings with the SEC. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
Pyxis Oncology Contact
Jennifer Davis Ruff
VP, Investor Relations
jdavisruff@pyxisoncology.com
FAQ
What is the date of Pyxis Oncology's investor meetings?
Who are the key executives attending the SVB Securities Global Biopharma Conference for PYXS?
How can institutional investors meet Pyxis Oncology's management during the conference?
What does Pyxis Oncology focus on in its research and development?
Where can I find more information about Pyxis Oncology?
